We have investigated the effects ofRo 31 -7549, a selective protein kinase C (PKC) inhibitor, on DNA synthesis and proliferation in two primary mouse epidermal keratinocyte culture systems. In differentiating keratinocytes incubated in medium containing 10% serum and high calcium (ap£roxi-mately 0.5 mM), [3H]thymidine incorporation indicated that Ro 31-7549 did not directly stimulate DNA synthesis but instead prevented the loss of proliferative capacity associated with continued culture in this medium. Maximal stimulation (2.6 times) of DNA synthesis was observed on day 4, whereas 0 N A synthesis at day 1 was unaffected. In a highly proliferative culture system using serum-free medium containing 25 ,uM calcium, TPA dose-dependently inhibited proliferation with an IC so of approximately 0.3 nM. This antiproliferative effect of TPA was largely reversed by 0.1,uM Ro 31 -7549. In the proliferative culture system, 0.75,uM Ro 31-7549 also essentially reversed the inhibition of proliferation caused by switching to high (1.0 mM) calcium. These results suggest that the loss of proliferative capacity in differentiating epidermal keratinocyte cultures may be mediated, at least in part, by PKC.] Invest DermatoI100: [240][241][242][243][244][245][246] 1993 differentiation. For example, PKC is a well-known cellular receptor for phorbol esters, which bind to and activate this enzyme [1]; in mouse skin in vivo phorbol esters are known tumor promoters [2, 3] . In primary cultures of murine keratinocytes phorbol esters, such as 12-0-tetradecanoyl-phorbol-13-acetate (TPA), elicit divergent responses of both proliferation and differentiation. Thus, TP A exposure results in the induction of both ornithine decarboxylase (ODe) and trans glutaminase (TGA), markers of keratinocyte proliferation and differentiation, respectively [4] [5] [6] . TPA also acutely (24 h) inhibits DNA synthesis [7] , due to the recruitment of a subpopulation of cells to a differentiated state [5, 8] ; the differentiated cells detach from the plate within 48 h and those remaining are resistant to the prodifferentiative effects of high calcium or a second TP A treatment [5] . On the other hand, prolonged (2-3 d) TPA treatment results in a marked stimulation of keratinocyte DNA synthesis [7] . This biphasic response to TPA is also observed in villo [2, 3] . Thus, using the pharmacologic agent TPA as a PKC activator, several investigators have obtained evidence to indicate the possible involvement of PKC in the regulation of keratinocyte proliferation and differentiation.
[3H]thymidine incorporation indicated that Ro 31-7549 did not directly stimulate DNA synthesis but instead prevented the loss of proliferative capacity associated with continued culture in this medium. Maximal stimulation (2.6 times) of DNA synthesis was observed on day 4, whereas 0 N A synthesis at day 1 was unaffected. In a highly proliferative culture system using serum-free medium containing 25 ,uM calcium, TPA dose-dependently inhibited proliferation with an IC so of approximately 0.3 nM. This antiproliferative effect of TPA was largely reversed by 0.1,uM . In the proliferative culture system, 0.75,uM Ro 31-7549 also essentially reversed the inhibition of proliferation caused by switching to high (1.0 mM) calcium. These results suggest that the loss of proliferative capacity in differentiating epidermal keratinocyte cultures may be mediated, at least in part, by PKC.] Invest DermatoI100: [240] [241] [242] [243] [244] [245] [246] 1993 differentiation. For example, PKC is a well-known cellular receptor for phorbol esters, which bind to and activate this enzyme [1] ; in mouse skin in vivo phorbol esters are known tumor promoters [2, 3] . In primary cultures of murine keratinocytes phorbol esters, such as 12-0-tetradecanoyl-phorbol-13-acetate (TPA), elicit divergent responses of both proliferation and differentiation. Thus, TP A exposure results in the induction of both ornithine decarboxylase (ODe) and trans glutaminase (TGA), markers of keratinocyte proliferation and differentiation, respectively [4] [5] [6] . TPA also acutely (24 h) inhibits DNA synthesis [7] , due to the recruitment of a subpopulation of cells to a differentiated state [5, 8] ; the differentiated cells detach from the plate within 48 h and those remaining are resistant to the prodifferentiative effects of high calcium or a second TP A treatment [5] . On the other hand, prolonged (2-3 d) TPA treatment results in a marked stimulation of keratinocyte DNA synthesis [7] . This biphasic response to TPA is also observed in villo [2, 3] . Thus, using the pharmacologic agent TPA as a PKC activator, several investigators have obtained evidence to indicate the possible involvement of PKC in the regulation of keratinocyte proliferation and differentiation.
Further complicating the interpretation of such TP A effects is the fact that the compound elicits two nearly concurrent events: PKC activation and PKC down-regulation [1] . Several investigators have reported that TP A treatment induces a ral?id but incomplete PKC down-regulation in mouse keratinocytes 19, 10] , as in many other systems. The question remains, however, as to which TPA-elicited effects are mediated by PKC activation and which are the result of down-regulation. Nevertheless, comparisons of the kinetics ofPKC down-regulation do not resolve this issue for several reasons, in- eluding 1) the aforementioned ability ofTPA to cause both activation and down-regulation of PKC; 2) the fact that there is a time delay of unknown duration between early signal-transduction events and such complex processes as DNA synthesis, proliferation, and differentiation; and 3) the apparent inability ofTPA to-induce complete down-regulation [9,10J, because the percentage of PKC activity required for a cellular response is unknown. Due to these difficulties, it has become apparent that compounds that selectively inhibit PKC in intact cells are needed to determine the role of this enzyme in cellular processes [11] .
Calcium is another keratinocyte regulator for which the role of PKC is unclear. Nevertheless, there is evidence to suggest that in this case also PKC activation and differentiation may be coupled: switching keratinocytes from low to physiologic extracellular calcium concentrations elicits both differentiation [12] and the formation of diacylglycerol (DAG) [13, 14] ' the natural activator ofPKe. Similarly, the addition of exogenous phospholipase C (PLC) to primary mouse epidermal keratinocytes results in the formation of DAG; like TPA, exogenous PLC also induces TGA and ODC [4] . In addition, synthetic DAGs have been reported to promote modest differentiative responses [15] . Furthermore, Isseroff et at [15] have observed effects of hi gh calcium on the subcellular distribution of PKe. Finally, inhibition of PKC activity, either by TPA-induced enzyme down-regulation or with the use of putative enzyme inhibitors, has been shown to prevent the differentiative effect of high extracellular calcium concentrations [16] . On the other hand, these non-selective PKC inhibitors have also been reported both to mimic and prevent the effects of TPA, on for instance ODC and TGA induction [17 -19] . Thus, although several lines of evidence indicate that PKC is involved in the regulation ofkeratinocyte proliferation and differentiation, the exact role of this enzyme is unclear. Again, the utility of a selective PKC inhibitor is obvious.
Recently, a series of bisindolylmaleimides has been shown to possess potent and selective inhibitory activity towards PKC in cellfree assays, with markedly reduced potencies towards cyclic adenosine monophosphate (AMP)-dependent and calcium/calmodulindependent protein kinases [20] . In addition, these PKC inhibitors inhibit in cellular assays both TPA-induced 47 -kD protein phosphorylation in platelets and phorbol-es ter-induced down-regulation of CD3 receptors in human T cells [20] ' Furthermore, the bisindolylmaleimide PKC inhibitors have been used by several investigators to demonstrate the involvement ofPKC in such cellular responses as cerebellar long-term depression [21] , the neutrophil respiratory burst [22] , fibrobl as t proliferation [11) , and mast cell histamine release and phospholipase D activation [23] . In the present study we have used one such bisindolylmaleimide PKC inhibitor, Ro 31-7549 (Fig 1) , to investigate the role of PKC in the regulation of keratinocyte proliferation.
MATERIALS AND METHODS
Cell Isolation and Culture Mouse epidermal keratinocytes were prepared according to the method of Marcelo et at [24] with minor modifications. Briefly, whole skin from 2-d-old neonatal PKC INHIBITION AND KERATINOCYTE GROWTH 241 CD-l mice was incubated at 4°C in HE PES [4-(2-hydroxyethyl)-Ipiperazine-ethanesulfonic acid]-buffered RPM I 1640 medium containing 0.25% trypsin overnight, followed by an approximate 45-min incubation at 37°e. After mechanical separation of the epidermis from the dermis with forceps, keratinocytes were detached and purified through a stepwise (12-20%) Ficoll gradient. Cells from the lower two layers were pooled, washed, and counted. For studies in a differentiative high-calcium, serum-containing medium, cells were plated in 96-or 6-well plates (Corning, Park ~idge, IL) at a density of 500,000 cells/cm 2 and cultured overnight m RPMI 1640 medium containing 10% fetal bovine serum, 100 units/ml penicillin, 100,ug/ml streptomycin, and 0.25 ,ug/ml funglzone at 32°C. Cultures were then treated with medium containing the test compounds and were refed every 1-3 d.
For studies in proliferating cu ltures, cells were plated in six-well plates at a denSity of 25,000 cells/ cm 2 in 10% fetal bovine serumcontaining RPMI 1640. Cells were allowed to adhere for 4 h in serum-containing medium after which time the cultures were ~ashed with phosphate-b~ffered saline lacking calcium and magneSIUm (PBS) and refed With a serum-free keratinocyte medium (SFKM) according to Yada et at [25J with minor modifications.
S~KM consisted of calcium-free ~lOdified Eagles' medium (SpecI~lty Media, Lafayette, NJ) contalI1l11g 25 ,uM calcium,S ng/ml epidermal growth factor, 1 mM glutamine, 90,ug/ml bovine pituitary extract,.ITS (5 ,ug/mll11sull11 + 5,ug/ml transferrin + 5 ng/ml sele?lO~s aCid), 0.05% bovl11e serum albumin (BSA), 100 units/ml pemclill11, 100 ,ug/ml streptomycin, and 0.25 ,ug/ml fungizone. Cells we~e I11cubated overmght at 37°C in the low-calcium, serumfree medIUm and were subsequently treated with medium containing the test compounds; cells were refed every 1-3 d. In some experiments ITS + (6.25 ,ug/ml transferrin + 6.25 ng/ml selenious acid + 5.35 ,ug/mllinoleic acid + 0.125% BSA) was substituted for ITS and 0.05% BSA. Determination of Cell Number Cells were washed with PBS and wer~ in.c~bated at 37°C with 0.5% trypsin to detach cells. Trypsl11 mlubltor was then added and the cells were triturated through an 18-gauge I?eedle to generate a single-cell suspension. An aliquot of thiS SllspenSlOn was added to 10 ml saline and cell number was determined using an electronic particle counter (Coulter Electronics, Hialeah, FL). 
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RESULTS
Ro 31-7549 has previously been demonstrated to potently inhibit PKC both in cell-free assays and in intact platelets and T cells in situ [20] -The ability ofRo 31-7549 to inhibit PKC activity in primary murine epidermal keratinocytes was investigated using the PKC activator TPA to initiate PKC-mediated cellular responses. Keratinocytes cultured in the differentiative high-calcium, serum-containing medium and pre-treated with various concentrations of Ro 31-7549, were exposed to 1IJM TPA for 24 h in the continued presence of the PKC inhibitor, and [3H]thymidine incorporation was measured. As illustrated in Fig 2A, (Fig 2A) , indicating that Ro 31 -7549 inhibits keratinocyte PKC. In Fig 2B is shown the effect ofRo 31-7549 alone on [3H]thymidine incorporation. At concentrations of Ro 31-7549 less than or equal to 2_5 11M, the PKC inhibitor alone had little or no effect on DNA synthesis after a 24-h exposure. At higher concentrations (> 2_5 11M) , Ro 31-7549 inhibited [3H]thymidine incorporation, likely as a result of cytotoxicity because protein synthesis decreased concomitantly (data not shown) . Taken together, the results shown in Fig 2A,B suggest that the reversal of the TPA inhibitory effect is the result of an inhibition of a PKC-mediated loss of proliferative capacity, rather than a direct enhancement of cell proliferation.
We then examined the effect of long-term exposure to various concentrations of Ro 31-7549 on cell growth . Primary keratinocytes cultured in the differentiative high-calcium, serum-containing medium were treated for 7 d with various concentrations ofRo 31-7549, and [3H]thymidine incorporation was determined. At lower concentrations (,.;;;5I1M) Ro 31-7549 alone dose-dependently stimulated (3HJthymidine incorporation with an EC so of approximately 0.25 11M (Fig 3) . A maximal increase in radio label of fourfold over control values was observed at a dose of 2.5 11M Ro 31-7549; in separate experiments a mean EC so of 0 .6 11M and a mean maximal stimulation of 2.6 times were obtained. Doses greater than 5 11M again inhibited D N A synthesis, presumably due to cytotoxicity as measured by a concomitant fall in protein synthetic rates (data not shown).
The time course of the stimulatory effect ofRo 31-7549 on DNA synthesis was subsequently determined. Cells in the differentiative high-calcium, serum-containing medium were treated for various time periods with 211M Ro 31 -7549 and DNA synthesis was measured. As shown in Fig 4, there was an inverse correlation between proliferative activity in control cultures (i.e., rates of[3H]thymidine incorporation [ Fig 4A] and DNA specific activity [ Fig 4BJ) and the extent of the stimulation of DNA synthesis elicited by Ro 31-7549. number. Keratinocytes cultured in SFKM were treated with various concentrations of TPA and cell number was determined initially and after 4 d of treatment. In the absence of TP A, cell number increased by 2.6-times from day zero (time of addition of TPA) . TPA dose-dependently inhibited proliferation with a 50% inhibitory concentration (IC so ) of approximately 0.3 nM (Fig 5) . Maximal inhibition of74% was observed at a concentrationofl0 nM. In a second experiment similar results were obtained although TPA exhibited a somewhat lower potency (IC so of about 1.5 nM). Thus, TPA potently inhibits proliferation of primary keratinocytes cultured in this serum-free medium. . TP A also elicited a characteristic rapid change in keratinocyte morphology, from the appearance of control cells illustrated in Fig  6A to , after a 6-h treatment, the "dendritic" morphology shown in Fig 6B. This morphologic change occurred quite rapidly: initial effects were observed after as few as 3 h of exposure to TP A, but the response was enhanced with longer periods (up to 4 d) of exposure (data not shown). As shown in Fig 6C, 0 .5,11M Ro 31-7549 abrogated this TPA-induced morphologic change. The ability of Ro 31-7549 to block this characteristic shape change was dose dependent in the range 0.1-1.0,l1M (data not shown), and incubation with Ro 31-7549 alone had little or no effect on keratinocyte appearance ( Fig 6D) . These results provide additional evidence that Ro 31-7549 is able to inhibit keratinocyte PKC. Data from several laboratories suggest that PKC may also be in~olved in the .antiproliferative effect of high calcium in primary epidermal keratmocytes [13 -16, 27 -30] . We therefore examined (1 mM) -calcium cultures, the increase in cell number from day 0 was 3.7 times and 2.7 times, respectively. Thus, switching to high calcium resu lted in an approximately 30% inhibition in culture growth over the 4-d period. Figure 8 shows that Ro 31-7549 dosedependently blocked this growth-inhibitory effect of calcium such that at a concentration of 0.75,LiM cell number was returned to control levels. This reversal occurred despite the fact that cell number in the presence of 0.75,LiM Ro 31-7549 alone was somewhat reduced (79% of the control value, data not shown). This result suggests that calcium-induced growth inhibition in proliferating keratinocytes may be mediated, at least in part, by PKC.
DISCUSSION
Several investigators have attempted to determine the r:ole of PKC in the regulation of keratinocyte growth and differentiation using reported PKC inhibitors, such as H-7 [1-(5-isoquinolinyl-sulfony l)-2-methylpiperazineJ, sphingosine, staurosporine, and bryostatin 1, with occasionally unexpected results. Certain inhibitors block some but not all PKC-mediated responses, whereas others may only partially inhibit such responses [18] . Still others behave in keratinocytes as partial agonists/antagonists, J?reventing some and mimicking other PKC-mediated effects [19J. And finally some "PKC inhibitors" act in these cells as PKC agonists, eliciting in some cases a greater response than the PKC activator TPA [17] .
Clearly, none of these PKC "inhibitors" is ideal for an investigation of the role of the enzyme in a cellular response; we, therefore, have used the selective PKC inhibitor Ro 31-7549 to study the possible involvement ofPKC in the regulation ofkeratinocyte proliferation. The abi lity ofRo 31-7549 to block the effect ofTPAon keratinocyte [3H]thymidine incorporation (Fig 2A), morphology (Fig 6) , and proliferation (Fig 7) indicates that the compound is able to inhibit keratinocyte PKC. This result is not unexpected, because Ro 31-7837, in addition to inhibiting PKC potently and selectively in cell-free assays, has previously been shown to prevent TPA-induced 47-kD protein phosphorylation in intact platelets and CD3-receptor down-regulation in whole human T cells [20] . Furthermore, a close structural analog ofRo 31-7549, GF 109203X, has been demonstrated to inhibit several PKC-mediated responses [11] . Thus, these bisindolylmaleimides are able to potently inhibit PKC activity both in cellular and cell-free assay systems and to block responses to the phorbol-ester PKC activators. Furthermore, the failure of Ro 31-7549 alone to increase (3H]thymidine incorporation (Fig 2B) or cell number (data not shown) suggests that the compound did not stimul ate DNA synthesis or proliferation directly but rather reversed the TPA-induced inhibition. Thus, our results suggest that inhibition of keratinocyte PKC maintains cellular proliferation.
The interpretation that PKC plays a role in the loss of proliferative capacity of cultured keratinocytes is further supported by the time course of the Ro 31-7549 -elicited increase in DNA synthesis (Fig 4) . On those days when control cultures were rapidly synthesizing DNA, the PKC inhibitor induced no or only small increases in [3H]thymidine incorporation and DNA-specific radioactivity, in comparison to the marked stimul atory effect ofRo 31-7549 on cells [TPA] The selectivity ofRo 31-7549 also would suggest that the agent is functioning through inhibition ofPKC activity. In ill vitro assay.s ~o 31-7549 demonstrates an approximate 60-and 200 times selectlVlty for PKC over cyclic AMP-dependent protein kinase (PKA) and calcium/calmodulin-dependent protein kinase, respectIvely [20] . The analog (GF 109203X) has also been shown to be highly selective for PKC both in cellular and cell-free assays [11] . Therefore, th.e ability of Ro 31-?549 to ~ti~u!ate [3H] . t~ymidi~e ~ncorporat~on ~s likely a result of Its PKC mhlbltory actiVity. TillS mterpretatlOn IS also supported by the ability of the compound to block effect~ of TPA (Figs 2, 6, and 7) , which is known to be a potent PKC activator. At higher concentrations, however, Ro 31-!54? would be predicted to inhibit many, if not all, cellular protem kmases; thus, the cytotoxicity exhibited by Ro 31-7549 at high doses (approxImately 2 .5 to 5 ,uM and above) is not unexpected. Nevertheless, because the primary effect we observed in this study was a sti~~la~io? of DNA synthesis and proliferation, the issue of cytOtOXICity IS Irrelevant.
• c. S. Harmon, J. Ducote, and D. Lutz (unpublished observations). T aken together, our results thus suggest that continued culture in a differentiative high-calcium, serum-containing medium results in a time-dependent PKC-mediated loss of proliferative capacity which is inhibited by Ro 31-7549. Our data suggest, therefore, that in keratinocytes PKC activation may playa role in a loss of proliferative potential, because blocking the activity of this enzyme stimulates proliferation. Paradoxically, the PKC-activating phorbol esters are also tumor promoters and prolonged exposure causes epidermal hyperplasia illl/ivD [2, 3] . However, in addition to their ability to activate PKC, with continual exposure phorbol esters can also cause the down-regulation ofPKC and depletion of its activity [1 ,9,1 0, 3 1] . In melanocytes, Brooks et al [32] have correlated phorbol ester-induced proliferation with down-regulation, and not transient activation, of PKC. Thus, the ability of phorbol esters to stimulate keratinocyte proliferation with chronic treatment may be related to their ability to cause down-regulation of PKC. This interpretation is further supported by the study of Hansen et al [33] who demonstrated that only those regimens of treatment with TPA or sll-l,2-didecanoylglycerol that induce PKC down-regulation also result in epidermal hyperplasia. It is not clear whether inhibiting PKC activity also inhibits down-regulation of the enzyme [34, 35] . Thus, further investigation is required to determine the effect of PKC inhibitors on down-regulation and tumor promotion.
The results presented here also suggest that PKC may be involved in the calcium-induced growth inhibition of keratinocytes (Fig 8) .
Such involvement is consistent with previous findings that high extracellular calcium concentrations induce phosphoinositide turnover and DAG production [1, 9, 10, 31] , events that usually result in PKC activation. Further support is provided by the observation that calcium induces subcellular redistribution ofPKC [15] . Dlugosz et al [16] have reported that bryostatin 1 treatment and TPA-induced down-regulation of PKC inhibit calcium-induced differentiation, again suggesting a role for PKC in the regulation of keratinocyte growth and differentiation. N evertheless, the lack of detectable PKC activation in Balb/MK cells exposed to high calcium [14] argues against an involvement ofPKC in calcium-induced diffe~en tiation; however, it should be noted that this cell line differentIates poorly relative to primary cultures of Balb/c keratinocytes [36] . Thus, although further study is necessary, it seems likely that PKC may play some role in calcium-induced regulation of growth and differentiation.
In this study we have demonstrated that the PKC inhibitor Ro 31-7549 prevented the PKC-mediated inhibition of DNA synthesis elicited by acute exposure to the phorbol ester tumor promoter, TP A. Furthermore, in cells cultured for several days in a differentiative high-calcium, serum-containing medium, Ro 31-7549 dosedependently stimulated DNA synthesis with an EC so of approximately 0.6 11M. The time course of DNA synthesis in cells cultured in the differentiative medium indicated that Ro did not directly stimulate DNA synthesis but instead maintained [3H]thymidine incorporation at elevated levels. Finally, in proliferating cells cultured in a serum-free medium, Ro 31-7549 prevented both calcium-and TPA-induced inhibition of proliferation. Thus, our results suggest that cells cultured with agents which promote differentiation suffer a gradual loss of proliferative capacity which may be mediated, at least in part, by protein kinase C.
